Longevity Peptide Stack — NAD+ + MOTS-c + Tesamorelin Research and the 12-Week Protocol

Longevity research has matured past single-compound interventions. The 2013 López-Otín "hallmarks of aging" framework identified twelve interrelated mechanisms — mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, and altered intercellular communication among them. A longevity peptide stack that targets multiple hallmarks at once has a better mechanistic case than betting on any single compound. The NAD+ + MOTS-c + Tesamorelin combination is the most-discussed research stack in Dubai's longevity-clinic-adjacent peptide community.

1. The hallmarks-of-aging framework

López-Otín et al. 2013 (and the 2023 update extending to twelve hallmarks) provides the mechanistic map that longevity-research peptide selection follows. Of the twelve hallmarks, peptide-tractable ones include:

• Mitochondrial dysfunction — declining respiratory chain efficiency, ROS accumulation
• Deregulated nutrient sensing — IGF-1, mTOR, AMPK, sirtuin axis
• Loss of proteostasis — declining protein quality control
• Altered intercellular communication — including hormonal signalling
• Stem cell exhaustion — declining regenerative capacity

The three-peptide stack targets the first two hallmarks directly (mitochondrial dysfunction, deregulated nutrient sensing) and modulates the fourth (intercellular communication via GH/IGF-1 axis).

2. The three peptides — what each one does

3. NAD+ — the coenzyme substrate

NAD+ declines roughly 50% between ages 30 and 60 (Camacho-Pereira 2016, Massudi 2012). The decline correlates with — but doesn't necessarily cause — multiple aging hallmarks. The functional consequence is reduced sirtuin and PARP activity, both of which require NAD+ as substrate. Restoring NAD+ to younger-adult levels is the proposed lever.

Subcutaneous NAD+ at 50-100 mg per session 2-3 times per week is the published case-series dosing. IV NAD+ at higher doses (300-1000 mg) is used in clinic settings; SC is the research-protocol home format. Full NAD+ context sits in our NAD+ vs NMN vs NR comparison.

4. MOTS-c — the mitochondrial signal

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome — discovered by Lee, Cohen et al. in 2015. The peptide translocates out of the mitochondrion under metabolic stress and acts as an exercise-mimetic signal: AMPK activation, increased glucose uptake, increased fatty acid oxidation. Reynolds et al. 2021 showed MOTS-c administration in aged mice extended running endurance by ~70%.

Research-protocol dose: 1-3 mg/day SC. The full mechanism walkthrough sits in our MOTS-c protocol research writeup.

5. Tesamorelin — the GH/IGF-1 axis

GH secretion declines roughly 14% per decade from age 20 onward (Veldhuis 2005). The decline contributes to sarcopenia, visceral fat accumulation, and reduced regenerative capacity. Tesamorelin (a stabilised GHRH analogue) drives endogenous GH pulse from the anterior pituitary at 2 mg/day SC. Falutz 2010 + Stanley 2014 show measurable visceral fat reduction + lean mass preservation/gain.

In the longevity stack, Tesamorelin addresses the GH/IGF-1 hallmark while contributing to body-composition endpoints that overlap with healthspan markers.

6. Mechanistic complementarity

The three peptides hit complementary points in mitochondrial and metabolic biology:

• NAD+ provides substrate for the enzymes that sense nutrient state and DNA damage
• MOTS-c sends the upstream stress signal that activates the broader metabolic-response network
• Tesamorelin drives the systemic anabolic/catabolic balance via GH/IGF-1

None of the three directly substitutes for any of the others. The mechanistic case for the stack is strong; the lack of combined-trial data is the limitation.

7. The 12-week protocol

Phase 1 (weeks 1-4): Ramp

• NAD+: 50 mg SC, Monday + Thursday
• MOTS-c: 1 mg/day SC, morning
• Tesamorelin: 1 mg/day SC, evening (45-60 min before sleep)

Phase 2 (weeks 5-12): Maintenance

• NAD+: 100 mg SC, Monday + Thursday (escalate from 50)
• MOTS-c: 3 mg/day SC, morning (escalate from 1)
• Tesamorelin: 2 mg/day SC, evening (escalate from 1)

Phase 3 (weeks 13-16): Off-cycle

• 4 weeks complete pause from all three peptides
• Re-baseline measurements before any next cycle

8. Injection logistics

Three separate injections. Never combined in one syringe. NAD+ stings more than the other two — slower push and use of a slightly more dilute concentration helps. The full vial math walkthrough sits in our peptide reconstitution calculator.

9. Tracking — what longevity research actually measures

Lifespan endpoints are decade-scale and unmeasurable in a 12-week protocol. The proxy endpoints longevity-research protocols use:

• Body composition: DEXA scan baseline + end-of-cycle (lean mass, visceral fat, total fat)
• Metabolic markers: Fasting glucose, HbA1c, fasting insulin, lipid panel
• IGF-1: Baseline + week 8 (Tesamorelin-driven elevation should sit within physiologic range)
• VO2 max or equivalent endurance metric: Useful for MOTS-c exercise-mimetic endpoint
• Sleep quality: Tesamorelin can improve deep-sleep proportion (GH-pulse-dependent)
• Subjective energy / cognition: Validated questionnaires (PROMIS, etc.) if available

10. The Dubai longevity-clinic context

Dubai's longevity-clinic sector typically packages NAD+ + Tesamorelin protocols at AED 4,000-8,000 per month inclusive of IV NAD+ and weekly Tesamorelin injection. The research-grade peptide stack at REVIVE LAB UAE pricing runs meaningfully below this on a per-month basis. The trade-off is self-administration responsibility vs clinic-supervised delivery.

Researchers who've completed a clinic protocol often graduate to research-grade self-administration for continuation cycles after they've validated their tolerability and protocol shape at the clinic.

11. Vial requirements for a 12-week cycle

This is a high-volume, longer-duration stack. UAE researchers running this protocol typically order in tranches rather than 12 weeks at once.

12. The caveats

• No combined-stack trial. The protocol synthesises separately-published evidence.
• Lifespan claims are unsupported. Healthspan markers are the measurable endpoint, not "anti-aging" in a literal sense.
• Tesamorelin and IGF-1 elevation. Cancer screening and family-history considerations apply to anyone running sustained GHRH protocols.
• NAD+ injection-site reaction. Sting and transient flush are common; not dose-limiting at SC route.
• Cost. Three injectable peptides + cycle structure is meaningfully more expensive than any single-compound protocol.

13. The summary

• NAD+ + MOTS-c + Tesamorelin target three different points in mitochondrial and metabolic biology.
• Protocol: 4-week ramp + 8-week maintenance + 4-week off-cycle.
• Inject separately; rotate sites; track healthspan proxy endpoints, not "lifespan."
• Dubai longevity-clinic pricing (AED 4-8k/month) is meaningfully above research-grade self-administration but provides clinical supervision.
• All three HPLC-verified at REVIVE LAB UAE with lot-level COA.